Equities researchers at CIBC began coverage on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in a report issued on Friday. The brokerage set a “market perform” rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the company. Evercore ISI set a $421.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, January 8th. Leerink Swann set a $448.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, February 11th. Chardan Capital raised Regeneron Pharmaceuticals from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $300.00 to $350.00 in a report on Monday, December 12th. Vetr cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $401.26 price target on the stock. in a report on Monday, December 12th. Finally, BTIG Research reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Fourteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $434.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 382.02 on Friday. The company has a market capitalization of $40.29 billion, a PE ratio of 49.62 and a beta of 1.44. The firm’s 50-day moving average is $371.86 and its 200-day moving average is $379.60. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $452.96.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The company had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same period in the previous year, the firm earned $2.83 EPS. The firm’s revenue was up 11.7% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals will post $12.95 EPS for the current fiscal year.
Your IP Address:
In other news, major shareholder Sanofi acquired 87,298 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 11th. The shares were acquired at an average price of $369.71 per share, with a total value of $32,274,943.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares in the last quarter. WFG Advisors LP increased its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares in the last quarter. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares in the last quarter. Live Your Vision LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $157,000. Finally, Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $160,000. 68.83% of the stock is currently owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.